Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
China · Delayed Price · Currency is CNY 4.430
+0.010 (0.23%)
Feb 4, 2026, 1:15 PM CST
SHE:300194 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,628 | 2,308 | 2,571 | 2,378 | 2,388 | 2,343 |
Other Revenue | 83.1 | 83.1 | 76.94 | 44.22 | 64.71 | 25.68 |
| 1,712 | 2,391 | 2,648 | 2,422 | 2,453 | 2,368 | |
Revenue Growth (YoY) | -35.66% | -9.68% | 9.33% | -1.28% | 3.58% | -14.83% |
Cost of Revenue | 1,068 | 1,174 | 1,281 | 1,066 | 935.97 | 839.22 |
Gross Profit | 643.17 | 1,218 | 1,367 | 1,355 | 1,517 | 1,529 |
Selling, General & Admin | 426.04 | 804.89 | 1,021 | 1,092 | 1,217 | 1,238 |
Research & Development | 160.78 | 153.22 | 148.79 | 142.89 | 120.38 | 86.94 |
Other Operating Expenses | 37.24 | 6.9 | 15.31 | 16.28 | 28.08 | 29.64 |
Operating Expenses | 638.18 | 968.97 | 1,182 | 1,255 | 1,370 | 1,353 |
Operating Income | 4.99 | 248.55 | 184.51 | 100.24 | 147.59 | 176.13 |
Interest Expense | -22.34 | -23.34 | -29.57 | -26.94 | -20.45 | -10.16 |
Interest & Investment Income | 150.16 | 106.8 | 109.41 | 90.07 | 74.46 | 53.65 |
Currency Exchange Gain (Loss) | 0.98 | 0.98 | 0.66 | 1.47 | -0.59 | -1.74 |
Other Non Operating Income (Expenses) | 4.05 | -0.45 | -0.85 | -1.4 | -1.76 | -0.61 |
EBT Excluding Unusual Items | 137.84 | 332.54 | 264.17 | 163.44 | 199.26 | 217.27 |
Impairment of Goodwill | - | - | -224.51 | -22.97 | -201.06 | - |
Gain (Loss) on Sale of Investments | -32.27 | -32.74 | 0.41 | 0.42 | 0.75 | 3.25 |
Gain (Loss) on Sale of Assets | -1.41 | 0.01 | 220.65 | 4.85 | 0.31 | 1 |
Asset Writedown | -5.51 | -4.92 | -3.61 | -2.44 | -626.17 | -2.69 |
Other Unusual Items | 38.72 | 17.3 | 33.24 | 46.07 | 34.93 | 22.29 |
Pretax Income | 137.37 | 312.2 | 290.36 | 189.35 | -591.99 | 241.12 |
Income Tax Expense | -4.75 | 34.03 | 55.95 | -11.47 | 17.61 | 35.35 |
Earnings From Continuing Operations | 142.12 | 278.17 | 234.41 | 200.82 | -609.59 | 205.77 |
Minority Interest in Earnings | 2.37 | 1.67 | -2.54 | 3.79 | 312.68 | 3.6 |
Net Income | 144.49 | 279.84 | 231.87 | 204.61 | -296.91 | 209.37 |
Net Income to Common | 144.49 | 279.84 | 231.87 | 204.61 | -296.91 | 209.37 |
Net Income Growth | -48.70% | 20.69% | 13.32% | - | - | -28.50% |
Shares Outstanding (Basic) | 1,152 | 1,166 | 1,220 | 1,204 | 1,188 | 1,163 |
Shares Outstanding (Diluted) | 1,152 | 1,166 | 1,220 | 1,204 | 1,188 | 1,163 |
Shares Change (YoY) | -6.03% | -4.46% | 1.40% | 1.34% | 2.10% | -0.70% |
EPS (Basic) | 0.13 | 0.24 | 0.19 | 0.17 | -0.25 | 0.18 |
EPS (Diluted) | 0.13 | 0.24 | 0.19 | 0.17 | -0.25 | 0.18 |
EPS Growth | -45.40% | 26.32% | 11.77% | - | - | -28.00% |
Free Cash Flow | -6.66 | 61.8 | 113.3 | -43.6 | -155.91 | -181.98 |
Free Cash Flow Per Share | -0.01 | 0.05 | 0.09 | -0.04 | -0.13 | -0.16 |
Dividend Per Share | 0.070 | 0.050 | 0.050 | 0.050 | - | 0.050 |
Dividend Growth | 40.00% | - | - | - | - | - |
Gross Margin | 37.58% | 50.91% | 51.63% | 55.97% | 61.85% | 64.56% |
Operating Margin | 0.29% | 10.39% | 6.97% | 4.14% | 6.02% | 7.44% |
Profit Margin | 8.44% | 11.70% | 8.76% | 8.45% | -12.10% | 8.84% |
Free Cash Flow Margin | -0.39% | 2.58% | 4.28% | -1.80% | -6.35% | -7.68% |
EBITDA | 193.6 | 445.63 | 392.88 | 284.11 | 321.89 | 331.9 |
EBITDA Margin | 11.31% | 18.63% | 14.84% | 11.73% | 13.12% | 14.01% |
D&A For EBITDA | 188.61 | 197.08 | 208.37 | 183.87 | 174.29 | 155.78 |
EBIT | 4.99 | 248.55 | 184.51 | 100.24 | 147.59 | 176.13 |
EBIT Margin | 0.29% | 10.39% | 6.97% | 4.14% | 6.02% | 7.44% |
Effective Tax Rate | - | 10.90% | 19.27% | - | - | 14.66% |
Revenue as Reported | 1,712 | 2,391 | 2,648 | 2,422 | 2,453 | 2,368 |
Advertising Expenses | - | 24.05 | 2.44 | 0.48 | 0.5 | 1.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.